Velcheti Gilotrif/ Afatinib in Squamous NSCLC

preview_player
Показать описание
Dr. Vamsidhar Velcheti, Hematology and Medical Oncology with the Cleveland Clinic Main Campus, joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses gilotrif/afatanib in squamous non small cell lung cancer.

  1. GRACE - Global Resource for Advancing Cancer Education
  2. GRACE
  3. CancerGRACE
  4. GRACEcast
  5. video podcast
  6. podcast
Рекомендации по теме
Velcheti Gilotrif/ Afatinib 0:04:09

Velcheti Gilotrif/ Afatinib in Squamous NSCLC

Afatinib treatment in 0:04:24

Afatinib treatment in squamous cell lung cancer – Video abstract [ID 104177]

New Targeted Therapy 0:02:57

New Targeted Therapy Lung Cancer Drug Gilotrif ( Afatinib )

Side Effect Management 0:03:08

Side Effect Management With Afatinib

Frontline Afatinib in 0:04:09

Frontline Afatinib in EGFR-Mutant NSCLC

Afatinib Vs Erlotinib 0:16:53

Afatinib Vs Erlotinib in Squamous Cell Carcinoma of Lung after failure of First line therapy

How, when, and 0:17:27

How, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR positive NSCLC

Gilotrif Approved as 0:00:15

Gilotrif Approved as Targeted First-Line Therapy for Patients With Metastatic NSCLC

MCNA Priority Review, 0:06:50

MCNA Priority Review, Afatinib Application Accepted, ASCO NSCLC Guidelines, and More

Afatinib in Patients 0:04:06

Afatinib in Patients With Uncommon EGFR Mutations

Afatinib for advanced 0:01:35

Afatinib for advanced EGFRm-positive NSCLC

Dr. Langer on 0:01:30

Dr. Langer on Afatinib for Advanced Non-Small Cell Lung Cancer

Sequential afatinib and 0:06:43

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

Afatinib vs erlotinib 0:06:52

Afatinib vs erlotinib in Chinese patients with advanced SCCof the lung- Video Abstract ID 161506

Gilotrif / Afatinib 0:05:34

Gilotrif / Afatinib

Medicines videos 0:00:15

Medicines videos

Study of 693 0:08:47

Study of 693 NSCLC patients treated with afatinib

Efficacy and Safety 0:03:07

Efficacy and Safety of Afatinib vs Erlotinib and Gefitinib in EGFR+ NSCLC

Phase 3 LUX-H&N1 0:03:32

Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma

Afanat Tab 30mg 0:00:05

Afanat Tab 30mg

LUX-Lung 7: Phase 0:02:14

LUX-Lung 7: Phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC

Dr. Velcheti on 0:01:42

Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC

Velcheti MET as 0:03:20

Velcheti MET as a Target in Advanced NSCLC

LUX-Lung 7: Phase 0:01:21

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line